Brachytherapy monotherapy may be sufficient for a subset of patients with unfavorable intermediate risk prostate cancer
- 1 April 2018
- journal article
- research article
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 36 (4) , 157.e15-157.e20
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Influence of Comorbidity on the Risk of Mortality in Men With Unfavorable-Risk Prostate Cancer Undergoing High-Dose Radiation Therapy AloneInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2016
- Is supplemental external beam radiation therapy necessary for patients with higher risk prostate cancer treated with 103Pd? Results of two prospective randomized trialsBrachytherapy, 2015
- Long-Term Efficacy and Toxicity of Low-Dose-Rate 125 I Prostate Brachytherapy as Monotherapy in Low-, Intermediate-, and High-Risk Prostate CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2015
- Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate ThemEuropean Urology, 2015
- Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate‐risk diseaseCancer, 2015
- Whole prostate D90 and V100: A dose–response analysis of 2000 consecutive 125I monotherapy patientsBrachytherapy, 2014
- A New Risk Classification System for Therapeutic Decision Making with Intermediate-risk Prostate Cancer Patients Undergoing Dose-escalated External-beam Radiation TherapyEuropean Urology, 2013
- Predicting biochemical tumor control after brachytherapy for clinically localized prostate cancer: The Memorial Sloan-Kettering Cancer Center experienceBrachytherapy, 2012
- Hormonal Therapy or External-Beam Radiation With Brachytherapy and the Risk of Death From Prostate Cancer in Men With Intermediate Risk Prostate CancerClinical Genitourinary Cancer, 2012
- Mortality in men with localized prostate cancer treated with brachytherapy with or without neoadjuvant hormone therapyCancer, 2010